Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of anal intraepithelial neoplasia in HIV-positive patients
2007-006277-92Phase 4Active
- Sponsor
- Academic Medical Center, department of infectious diseases
- Start
- Nov 2007
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of imiquimod and fluorouracil in anal intraepithelial neoplasia (AIN) and human immunodeficiency virus infection (HIV) (3 arms), sponsored by Academic Medical Center, department of infectious diseases. Primary endpoints: Histological resolution at 4 weeks, Relapse rate at 24 weeks and 2 more. Started Nov 2007; status: active.
02
Drugs
imiquimodfluorouracil
03
Conditions
anal intraepithelial neoplasia (AIN)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2007-006277-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006277-92.